Conduct of the Program. (i) The Research Program will be conducted by each Party pursuant to and consistent with the Research Plan.
(ii) Subject to the terms and conditions of this Agreement, each Party shall be responsible for managing and controlling their personnel and performing their respective tasks pursuant to the Research Plan.
(iii) Each Party shall conduct the Research Program in good scientific manner, and in compliance in all material respects with all requirements of applicable laws, rules and regulations.
(iv) Each Party shall use Commercially Diligent Efforts in the Research Program, including without limitation allocation of sufficient time, effort, equipment and facilities to the Research Program, and shall use personnel with sufficient skills and experience as are required to accomplish the Research Program in accordance with the terms of this Agreement and the Research Plan.
(v) Notwithstanding anything else to the contrary in this Agreement, all activities conducted under the Research Program shall continue only until expiration of the Research Program Term.
Conduct of the Program. Each party shall conduct its obligations under the Program in good scientific manner and in compliance in all material respects with all requirements of applicable laws and regulations and all applicable good laboratory, clinical and manufacturing practices, to attempt to achieve its objectives efficiently and expeditiously. Each party shall allocate sufficient time, effort, equipment, facilities and personnel with sufficient skills and experience to the Program to conduct its obligations under the Program and to accomplish the objectives thereof.
Conduct of the Program. The Program shall be performed by Virpax in the Territory. Under the direction and supervision of the JRC, Virpax shall (a) perform or cause to be performed its obligations under the Program in good scientific manner and in compliance in all material respects with all Applicable Law, including good laboratory practices and good clinical practices, and (b) allocate sufficient time, effort, equipment and skilled personnel to complete such activities successfully and promptly. Following the New Effective Date, Virpax shall promptly commence the Program.
Conduct of the Program. Forms of cooperation under this Memorandum will be collaborative efforts determined between DOI, USAID, host governments, and stakeholders, geared toward increasing local capacity for improved resource management in selected geographic areas (Program). Activities under this MOU are subject to the availability of personnel, resources, and funds. This Memorandum should not be construed to obligate any particular expenditure or commitment of resources or personnel. The Participants intend, in accordance with Article VI below, to develop specific Annexes in writing before the commencement of each project (Project) hereunder. Each Participant should designate a principal representative, who, as mutually determined by the Participants, should meet to review the activities under this MOU and develop proposals for future activities, as appropriate.
Conduct of the Program. 1. The Parties shall be responsible jointly for direct transaction of mat ters of Program policy and for the overall coordination of the Program. Each Party shall designate a Program Officer who shall be the principal point of con tact for the other Party in the conduct of the business of the Program.
2. For proposals from researchers of their respective sides, the Parties shall receive, evaluate for merit, and ensure conformance with the provisions of this Memorandum. Proposed activities may be incorporated into this Program only upon approval of the Parties.
3. The Parties shall seek to facilitate the granting of visas and other forms of official permission for entry into and exit from their respective national territories of participating individuals, and seek to waive the custom duties on equipment and supplies required to carry out an approved activity according to the laws and regulations of each country.
Conduct of the Program. It shall not be considered a breach of this Agreement by either Party if an objective of the Program is not achieved due to a delay caused by the other Party.
Conduct of the Program. (a) Cubist represents that it has disclosed true and correct copies of its Hiring Profiles for its Sales Force and CSD Force. If Cubist desires to modify any Hiring Profile in a manner that would reduce the minimum qualifications for a position on the Sales Force or CSD Force, Cubist shall notify AstraZeneca in writing of such proposed modification and provide AstraZeneca at least ten (10) business days to comment on such proposed modifications, which comments, if any, shall be considered in good faith by Cubist prior to implementing any such modification.
(b) Cubist shall make available its Alliance Manager and appropriate management personnel to periodically accompany (i) Representatives on Calls to Target Prescribers and to review whether the conduct of such Calls is consistent with the terms of this Agreement, and (ii) CSDs to review whether the conduct of the CSD Activities is consistent with the terms of this Agreement.
(c) The Representatives shall remain exclusively under the supervisory authority of Cubist and Cubist’s field management. The CSDs shall remain exclusively under the supervisory authority of Cubist and Cubist’s CSD manager(s).
(d) Cubist shall not disseminate any information to the Representatives []* unless dissemination of such information to the Representatives has been approved in writing by AstraZeneca. Cubist shall provide at least ten (10) business days written notice to AstraZeneca’s Alliance Manager prior to dissemination of any such information to the Representatives, and AstraZeneca shall notify Cubist in writing within ten (10) business days after it receives such notification as to whether or not AstraZeneca approves the dissemination of such information; []*. If AstraZeneca does not respond within such ten (10) business day period, then AstraZeneca shall be deemed to have approved the dissemination of such information to Representatives. Any such information disseminated by Cubist shall comply with Applicable Law and the Business Policies (to the extent consistent with Applicable Law and this Agreement).
(e) AstraZeneca shall provide to Cubist information sufficient to allow the Representatives to discuss Product pricing (i) consistent with the Sales Training Materials or *Confidential Treatment Requested. Omitted portions filed separately with the Commission.
Conduct of the Program. The Program shall be performed by Virpax in the Territory. Under the direction and supervision of the JRC, Virpax shall (a) perform or cause to be performed its obligations under the Program in good scientific manner and in compliance in all material respects with all Applicable Law, including good laboratory practices and good clinical practices, and (b) allocate sufficient time, effort, equipment and skilled personnel to complete such activities successfully and promptly. Following the Effective Date, Virpax shall promptly commence the Program, provided, however, that Virpax shall not be obligated to initiate any activities under the Clinical Development Plan until the Funding has been fully received by Virpax or Virpax has notified Nanomerics in accordance with section 13.5.1.1 that it has secured equal or greater funding from a Third Party source which is available and intended for the Program.
Conduct of the Program. The Program shall be conducted in online or in-person, synchronous or asynchronous format and shall be developed, delivered, and maintained by UMD in compliance with the regulatory norms and statutory rules and regulations of concerned authorities and statutory bodies applicable at the relevant time and in accordance with the terms of this Agreement. Details of the Program to be initiated under this Agreement shall be agreed upon by both Parties in the format provided in Attachment A. UMD’s Technical Contact (identified above) shall be Sponsor’s main point of contact.
Conduct of the Program. During the Collaboration Term and under the direction and supervision of the JRC, each Party shall (a) perform or cause to be performed its obligations under the Program in good scientific manner and in compliance in all material respects with all Applicable Law, including good laboratory practices and good clinical practices, and (b) allocate sufficient time, effort, equipment and skilled personnel to complete such activities successfully and promptly. Following the Effective Date, the Parties shall promptly commence the Program, provided, however, that neither party shall be obligated to initiate any activities under the Clinical Development Plan until the Funding has been fully received by Virpax. Each Party shall assume responsibility for its own costs and expenses for the Program or as otherwise might be agreed in writing.
